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Abstract
Conducting clinical trials to prevent and treat infectious diseases in pregnancy is essential to 
saving maternal and newborn lives, though it is fraught with challenges. We have been conducting 
research in malaria treatment and prevention in children and pregnant women in Blantyre, Malawi 
for over a decade. Here, we review some of the unique challenges that we have faced in leading 
research studies that with rigor and integrity and maintaining the highest ethical standard. We 
conclude with concrete strategies to overcome some of the apparent obstacles that frequently focus 
on building trust through bidirectional communication with local health workers and communities. 
We also highlight the key role of local and international investigators to advocate for the health of 
the communities in which they work.
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 1. Introduction
Most clinical researchers would have had the experience of a disease sharply decreasing in 
prevalence, or even virtually disappearing, while the disease is under study. The conditions 
of a clinical trial often alter the natural history of diseases and the prevalence of adverse 
outcomes. These complicating factors limit the ability to conduct ethical studies that provide 
generalizable information, especially in resource-limited settings, where the reality of access 
to health care and disease prevention is often much less than the stated standard of care [1]. 
In addition, it contributes to the failure to conduct adequately powered studies to detect 
differences between treatment and control groups because the overall rate of either the 
disease or adverse outcome of interest decreases significantly due to the conditions of the 
clinical trial.
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The challenges of conducting clinical studies among pregnant women have been well 
articulated in previous reviews [2,3]. Our review focuses on unique challenges of clinical 
trials in resource limited settings using illustrative examples; our research group has 
encountered conducting studies to evaluate strategies to prevent and treat malaria among 
pregnant women in Malawi. We highlight common issues that would apply to a wide range 
of diseases. We end the discussion with several key lessons learned from our experiences 
and strategies that have overcome some of the challenges that we and others have faced. This 
discussion is not intended to be exhaustive but rather a framework in which to consider and 
trouble-shoot the unique obstacles.
 2. Typical scenario
In clinical trials, to treat or prevent infectious diseases in pregnant women, the study design 
is typical. Pregnant women at risk of an infectious disease are enrolled at a standardized and 
often early point in their pregnancy when they are assumed to be uninfected. At baseline, all 
participants are expected to be at a similar risk of an incident infection over the course of 
their participation. They are randomized to receive either the intervention or a place boor 
standard of care. The primary aim is to measure the effect of the intervention on the 
incidence of an infection during pregnancy or in the infant or on the cure rate. The additional 
key aim is often to assess the safety of the intervention by measuring its impact on maternal, 
perinatal and fetal outcomes.
Prospective participants undergo a screening process to ensure that they meet specified 
eligibility criteria and to exclude women who may be at increased risk of harm through 
study participation. In many cases, the women and their pregnancies are scrutinized and 
followed carefully. Accurate and complete capture of perinatal outcomes is often essential to 
assessing the safety of interventions during pregnancy [4].
 3. Study design
 3.1. Sample size considerations
Studies are designed based on baseline data, collected through previous studies or public 
records. The prolonged process from grant writing to start of the study virtually ensures that 
baseline data will be outdated by the time the new clinical trial begins. This is true for 
designing clinical trials in all settings as secular and seasonal variations are the hallmark of 
communicable diseases. In resource limited settings, the added elements of sporadic and 
unpredictable availability of resources lead to changes in preventive strategies available in 
the general community. As an example, in our continuous surveillance of malaria prevalence 
in pregnant women and in communities, we have consistently found that a single bed net 
campaign may decrease malaria prevalence dramatically for one year and then return to the 
previous baseline level subsequently (Boudova and Laufer, unpublished data). Public records 
are also unreliable and inconsistent. Definitions that distinguish stillbirths from miscarriages 
and growth restriction from preterm birth require accurate antenatal assessment of 
gestational age, which is rarely available [5].
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Another unique characteristic of research in the most resource-limited environments is the 
disparity between standard of preventive and curative treatment policies and the access that 
most women have to those treatments [1,6]. As discussed below, investigators are obligated 
to provide clinical trial participants with, at least, the basic care to which they are entitled. 
While this obligation is essential, when such services are not available to the population at 
large, such care alone will likely have an effect on the natural history of a wide range of 
infectious diseases and also the incidence of adverse perinatal and neonatal outcomes. A 
significant decrease in baseline rates of these key outcome measures can limit the power of 
clinical studies. In our studies, the provision of bed nets to prevent malaria is a key element 
of the antenatal care package, though the local government clinic frequently experience 
stock outs. Active detection and treatment of anemia, hypertension, urinary tract infections 
and sexually transmitted diseases that often does not occur in busy public clinics, likely 
improves the perinatal and infant outcomes among all participants.
 3.2. Eligibility criteria
To ensure some uniformity in the study population, gestational age windows are specified in 
the eligibility criteria [2]. Assessment of gestational age of the pregnancy is typically 
performed by calculation based on last menstrual period or measurement of the fundal 
height. Even when implemented correctly, these techniques do not provide consistent results 
[7–9]. In our experience, women often do not recall their last menstrual period and busy 
midwives often do not have time to measure the fundal height or do not have measuring 
tapes. Visual inspection and palpation of the abdomen are used to give a rough estimate of 
gestational age. For a clinical trial, more precise measurements are required and the use of 
ultrasound dating is essential. Portable and inexpensive ultrasound machines are now 
available for use in resource-limited settings [10]. However, this capacity to accurately date 
pregnancies requires training and supervision as described below.
When participants are expected to be enrolled prior to the third trimester, recruitment may be 
difficult. Reaching women during the early stages of their pregnancy poses a challenge. 
There are social concerns about revealing ones pregnancy “too early”. Women typically 
present for their first antenatal visit late in their second or even in their third trimester [11–
14], limiting the ability to capture data during early fetal development.
 3.3. Follow up
The ability to maintain the follow up schedule through pregnancy has been identified 
previously as a barrier to obtaining adequate safety data [2]. Follow up fatigue often sets in. 
The World Health Organization recommends a minimum of four antenatal care visits. For 
active case detection, administration of interventions and monitoring for adverse events, 
participants are often asked to attend more antenatal visits than this commonly-accepted 
minimum. Although, transportation costs are reimbursed for participants at all scheduled 
visits, increased antenatal visits compete with other obligations for participants as well as 
the physical fatigue of pregnancy, all contributing to the risk of reduced adherence to follow 
up schedules over time.
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There are local traditions that encourage women to deliver their infants at health facilities 
located close to their extended families. These customs are essential because family 
members provide all care for pregnant women and their newborns. Although, we only 
included women who agreed to deliver their infant at the study designated health center; we 
found that delivery plans changed over the course of the pregnancy. As the first antenatal 
visit coincided with the first public statement of the woman’s pregnancy, negotiations about 
details of the delivery, especially, for women who are pregnant for the first time, evolve over 
the subsequent months.
Changes in participation as a result of adverse events experienced during the study 
significantly threaten the integrity of the study. We have observed a wide range of responses. 
Most often, when complications related to pregnancy occur, participants are grateful to the 
study team members for the medical care, logistical support and advocacy they provide. 
Research clinicians and nurses are able to help navigate the often complex health system and 
provide care that is better than what is available through the typical public health 
infrastructure. However, adverse events, even when clearly unrelated to study intervention, 
often elicit suspicion and fear. As a result, women who experience complications of 
pregnancy either choose to discontinue study participation or withdraw due to pressure from 
family members who attribute the complication to research participation. In these cases, loss 
to follow up is strongly associated with pregnancy outcomes.
 3.4. Detection of baseline illnesses and exclusion criteria
The eligibility criteria, especially, for trials of new interventions that may have unanticipated 
risks, are often strict. Potential participants undergo extensive evaluation, often well beyond 
the standard screening offered to women in the antenatal settings, to assess their eligibility 
for the study. Thus, women who would have underlying illnesses that would otherwise 
remain undetected at an early stage will be systematically excluded from the clinical trial. 
This is undoubtedly essential for the protection of the welfare of those who enroll. However, 
conclusions about safety and efficacy in a real life population are severely limited. Outcomes 
will be demonstrated in women with or without conditions, which were identified through 
screening tools that may never be avail-able in routine setting, so a conclusion, for example, 
that a drug is safe as long as a pregnant women do not have hypertension may not be 
relevant in the setting where blood pressure is not carefully monitored.
 3.5. Capturing endpoints
Deliveries are unpredictable. They occur day and night, though typically more often in the 
night [15]. This trend has not been maintained recently in the United States [16], but likely 
remains true in resource-limited settings. They can occur in any location, not always at a 
health facility and certainly not at the previously identified health facility of choice. 
Capturing data from maternity wards is perhaps one of the most challenging of all health 
care environments. They are chaotic places where frequently a single nurse midwife is 
overseeing multiple women in labor and may be responsible for both maternal and neonatal 
care during the delivery. Women are discharged home quickly, with limited assessment of 
the infant. While birth weight is often recorded, its accuracy is not assured. Other key 
measurements such as height and head circumference may not be routinely recorded. Often 
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temperature is not measured routinely so fever and hypothermia are usually not detected 
until it is severe.
 4. Cultural, ethical and regulatory concerns
 4.1. Consent
One of the basic tenets of research ethics is autonomy – individual’s capacity to deliberate 
about own goals and to act under the direction of such deliberation without manipulation by 
external forces [17]. Individual autonomy is more complex in settings where community and 
family structures have a strong influence on individual choices. This is a unique challenge to 
pregnant women as the decisions that affect the fetus often are perceived to lie with people 
other than the mother. Subpart B of 45 Code of Federal Regulations Part 46 clearly states 
that for studies in which the risk to the fetus is not greater than minimal, consent of just the 
pregnant woman is sufficient [18]. However, our experience is that this is not how decisions 
are made. Key influential family members, especially mother in law and other paternal 
matriarchs are often the decision makers. Although, consultation with family members does 
not negate individual autonomy, in fact is an exercise of it, this does present some unique 
challenges.
For studies that seek to enrol women at their first antenatal visit, the need to consult 
individuals who are not present during the visit is problematic. If randomization to an 
intervention vs. standard of care is meant to occur at the first antenatal visit, then a delay in 
provision of at least a standard intervention raises the concern that a potential participant 
will receive inadequate antenatal care while she is deciding whether or not to join the study. 
The period without the protection of standard antenatal intervention may increase the period 
of the pregnant woman’s vulnerability to infection and there is a risk that the woman will not 
return in a timely manner especially if she decides against study participation. Our staff 
routinely asks potential participants if there are other key decision makers with whom they 
would like to discuss their participation prior to enrolment. However, we have experienced 
substantial numbers of withdrawals of consent following first visits because of the input of 
influential family members. It is tempting to insist upon identifying and consulting key 
decision makers, however, this also disempowers the woman from making decisions.
 4.2. Trust
Enrolment into a study depends on how much trust the potential participant has in the study 
and its staff. This trust is largely based on the expectation that the study will maximize good 
and minimize harm. With pregnancy, these expectations are held even more strongly with 
the anticipation of healthy outcomes and the intuitive understanding that bad outcomes can 
occur without warning. In a setting of extended families and strong community bonds, the 
study needs to gain the trust of not only the participants, but also their husbands, parents and 
traditional leaders. The community carefully scrutinizes any new activities that are related to 
pregnancy health care. Mistrust can develop quickly and can breed misconceptions that have 
the potential to derail study recruitment and follow up. In our study, the common 
misconceptions were that the study team collects human specimens including blood and 
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placentas for profit gains or witchcraft. Other community members have claimed that study 
participation leads to poor pregnancy outcomes and infant death.
 5. Generalizability
As it is clear from the above discussion, participants who attend antenatal care within the 
desired gestational age range, have family support and meet the strict inclusion and 
exclusion criteria, represent a unique subset of pregnant women. Through their participation 
in the clinical trial, they undergo screening and treatment for many infectious and non-
communicable conditions that will alter pregnancy outcomes. The question then always 
arises – To what extent does the outcome of the clinical trial predict the impact of 
implementation of the intervention under real-life conditions?
 6. Proposals to prevent and mitigate
 6.1. Partnering with local health care providers
The local health care facilities providing maternal care can play a pivotal role in recruitment 
of participants and tracking of delivery outcomes. In our studies at a local health center, 
nurse midwives from these facilities were trained on the specifics of the studies, including 
participant recruitment, identification of a study participant in labor and collection of 
delivery outcomes. Though there is inherent tension between government and study 
personnel and assigned duties and responsibilities, the local study team focused intensely on 
maintaining a collegial and cooperative relationship with the local health center staff.
Another level of partnership was with community health care workers (CHWs), whose 
formal job is implementation of public health interventions at community level and are often 
consulted by community members on various health topics. The CHWs were trained on the 
details of the clinical studies, the screening process and basics of what potential participants 
should expect if they choose to join the study. Their involvement was instrumental in 
engaging in a strong working relationship with the community. They also serve as trusted 
advisors to community members and especially appeal to individuals who have some 
inherent distrust of the government health infrastructure. Thus, in addition to facilitating 
communication, they also helped the study to gain acceptance.
 6.2. Community engagement
To maintain strong lasting ties with the community, the site, with the help of the research 
ethics committee, established a community advisory group, a committee of volunteers from 
the study catchment area trained on the basics of clinical trials, research ethics and the 
specifics of ongoing studies. The group represents the interests of the community with 
regard to ongoing and new studies. It also acts as a liaison between the research team and the 
community, educating people about participation in clinical trials and providing a platform 
of ongoing communication between the research team and the community.
Because of the reluctance to reveal pregnancy early, it is difficult to encourage discussion 
about pregnancy related issues prior to initiating antenatal care. There is no specific target 
audience for women who are pregnant but have not reached antenatal care, the fathers of 
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their children and their parents. Information must reach the entire community with the hope 
that in the short period between revealing pregnancy and attending the first antenatal clinic 
visit, study participation is discussed.
To reach out to men, parents and others with influence over women’s participation in clinical 
studies that are otherwise not accessible because they do not attend antenatal clinics, site 
staff conducted community meetings around the catchment area. To attract these key 
decision makers, the activities were organized in a formal way through community leaders 
and included performance by a local drama group. The activities targeted common 
misconceptions about study participation and pregnancy outcomes and accommodated 
questions from community members to address their concerns.
 6.3. Basic use of ultrasound
The use of ultrasound for dating pregnancies prior to the third trimester is an attainable goal. 
Portable, rugged ultrasound machines are available for use in resource limited settings for a 
wide range of obstetric and non-obstetric uses. We have successfully established on-site 
ultrasound capacity for gestational age dating in the second trimester at our research clinic in 
Malawi [19]. A US trained obstetrician spent one week in person training key staff members 
in the technique. For four months, the US expert reviewed all scans and provided real-time 
feedback. With the intense quality control procedures, several site staff became highly 
skilled in this specific activity. They subsequently trained new staff members and served as 
their mentors as the new trainees began to conduct the scans themselves. Today, we conduct 
10–15% quality assurance on all scans to ensure that the quality remains high. The endeavor, 
however, is not trivial.
 6.4. Providing benefits to early enrolment in antenatal care
In the absence of interventions that get at the very deep seeded reluctance among women to 
identify themselves as being pregnant [20–22], clinical studies can offer incentives to early 
enrolment in antenatal services. One obvious benefit in studies is the relief of the costs of 
antenatal care to the individual woman. In this way, one of the leading barriers to antenatal 
care attendance, lack of economic means to register for care [12,23,24], can be overcome. 
With this support, the first antenatal visit may be perceived as less of an investment and thus 
a decision that can be made earlier in gestation.
The ultrasound images are also novel and often highly desirable benefits of study 
participation and potentially incentive to seek out antenatal care. If there are limited tangible 
benefits to enrolment in antenatal care and the care itself does not provide adequate 
reassurance about the viability of the pregnancy, a live image of the fetus and a picture to 
take home to show to family members has been strongly appreciated by study participants. 
Investigators in other Africa settings have had similar anecdotal experience [14,25,26] and a 
clinical trial is currently underway to assess the benefit of routine ultrasounds in resource-
limited settings with the rigor of a randomized trial [27].
One unanticipated benefit was the ability to conduct urine pregnancy tests. This capacity 
was not available at the government clinic from which we recruited study participants. 
Young women in their first pregnancy occasionally came to the government clinic to 
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ascertain whether they were pregnant and through the standard care, pregnancy would be 
diagnosed by history of last menstrual period and palpation, which was often indeterminate 
early in pregnancy. Women who were interested in being screened for study participation 
were offered urine pregnancy test if pregnancy was not clear from physical examination. 
These women were grateful for the service provided by the study team and were eager study 
participants when they were enroled.
 6.5. Flexibility and re-evaluation
Because of the unpredictable nature of communicable diseases and the potential of 
unanticipated and sometime unmeasurable factors that influence the local epidemiology, 
sample size and event rate calculations must allow for some flexibility. Changes in the 
incidence of disease and adverse outcomes should be anticipated and opportunities for re-
evaluation should be built in to protocol time lines. Sponsors should also be prepared to 
support changes in these parameters when unpredictable fluctuations occur.
 6.6. Advocacy
Researchers from the local institutions and from abroad are in a unique position of power. 
They often develop close working relationships with public health leaders, make meaningful 
contributions to the health care provided in the community where they work and help to 
translate scientific discoveries into public health action. By functioning in close association 
with the public health system, investigators experience first-hand the challenges faced by 
local health centers. We therefore have an opportunity and even a responsibility to advocate 
on behalf the communities we serve. There is a selfish view of this – by making the access to 
healthcare in “real life” more similar to the conditions of clinical trials, we improve the 
generalizability of our results – but we believe we have a moral obligation. Communities 
trust that researchers are working to improve their health. While researchers think of this 
role as contributing new scientific knowledge, we can and should have an obligation work to 
make the best possible health care today available to those communities who are willingly 
volunteering to improve the health of those who come after them.
 7. Conclusion
Conducting clinical trials among pregnant women in resource limited settings presents 
unique epidemiological and ethical challenges including limited availability of baseline data, 
the quality of standard of care when compared to international standards, unpredictable 
changes in disease epidemiology and cultural beliefs. In our decade of leading clinical 
studies of pregnant women in Malawi, we have found that partnering the local health care 
system, community engagement, incentivizing study participation, and adding flexibility to 
study designs are essential to maintaining a successful program.
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